Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data
Sign Up to like & getrecommendations! Published in 2022 at "Neurological Sciences"
DOI: 10.1007/s10072-022-05870-x
Abstract: Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor which has been found effective even for the treatment of chronic migraine (CM) complicated with medication overuse headache (MOH). According to the present guidelines,… read more here.
Keywords: month; erenumab suspension; number; chronic migraine ... See more keywords